Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Prenatal diagnosis Stories

2012-05-23 02:25:38

SAN JOSE, Calif., May 23, 2012 /PRNewswire/ -- Ariosa Diagnostics, a molecular diagnostics company, announced today the publication of a study that provides more information on the factors which may influence the amount of fetal DNA found in maternal blood. The study was led by Professor Kypros Nicolaides, MD, of Harris Birthright Research Centre for Fetal Medicine at King's College Hospital in the United Kingdom. (Logo: http://photos.prnewswire.com/prnh/20120326/NY75864LOGO ) The study...

2012-05-18 02:24:08

SAN DIEGO, May 18, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that a new publication from the large Women & Infants multi-center clinical study on the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT) has been published online in the peer-reviewed journal, Prenatal Diagnosis. Along with this week's publication, the Company announces that...

2012-05-07 02:33:09

SAN JOSE, Calif., May 7, 2012 /PRNewswire/ -- Ariosa Diagnostics, a molecular diagnostics company, today announced that the Harmony(TM) Prenatal Test will be available in the United States and Canada through Laboratory Corporation of America® Holdings (LabCorp®) and Integrated Genetics, a member of LabCorp's Specialty Testing Group. Harmony represents an innovative non-invasive test for detection of common fetal trisomies utilizing a directed approach to analyze cell-free DNA (cfDNA)...

2012-05-01 02:32:30

SAN JOSE, Calif., May 1, 2012 /PRNewswire/ -- Ariosa Diagnostics, Inc., a molecular diagnostics company, is pleased to announce that Thomas J. Musci, M.D. will lead the clinical development and medical affairs of the company. (Logo: http://photos.prnewswire.com/prnh/20120326/NY75864LOGO) Dr. Musci is board-certified in Maternal-Fetal Medicine and Genetics and has had an extensive career in academics, private practice and industry. Recognized as a leader in clinical research on prenatal...

2012-04-25 02:32:23

REDWOOD CITY, Calif., April 25, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today announced the peer-reviewed publication of a new health economic model for its verifi(TM) prenatal test that clearly demonstrates the clinical and economic value of integrating the verifi(TM) prenatal test into current prenatal screening algorithms. The model shows a dramatic reduction in both the number and cost of invasive...

2012-04-12 06:26:47

-- A unique birth facility exclusively for mothers carrying babies with known birth defects who need fetal surgery or immediate specialized care after birth PHILADELPHIA, April 12, 2012 /PRNewswire-USNewswire/ -- Less than four years after opening the Garbose Family Special Delivery Unit, the world's first birth facility exclusively for mothers carrying babies with known birth defects, The Children's Hospital of Philadelphia (CHOP) celebrates 1,000 deliveries. All babies delivered...

2012-03-26 02:26:35

ATLANTA, March 26, 2012 /PRNewswire/ -- Beginning today, Northside Hospital and Atlanta Perinatal Consultants announce the availability of an affordable, safe and advanced screening test for common fetal trisomies, such as trisomy 21 that causes Down syndrome and trisomy 18 that causes Edwards syndrome. The Harmony Prenatal Test, developed and offered by Ariosa Diagnostics utilizes a novel testing platform to analyze DNA in maternal blood so as to provide more accurate and personalized risk...

2012-03-26 02:25:45

SAN JOSE, Calif., March 26, 2012 /PRNewswire/ -- Ariosa Diagnostics (formerly Aria Diagnostics), a molecular diagnostics company, today announced the completion of its clinical validation study for the Harmony(TM) Prenatal Test. The multi-national study represents the largest clinical study performed to date for non-invasive prenatal detection of common fetal trisomies. The test utilizes a directed, non-invasive approach to cell-free DNA (cfDNA) analysis in maternal blood. Additionally,...

2012-02-23 14:00:00

HOUSTON, Feb. 23, 2012 /PRNewswire-USNewswire/ -- As one of the country's leading medical centers diagnosing and treating fetal anomalies, Texas Children's Fetal Center is proud to announce the birth of Baby Charlotte, the team's first patient to undergo in-utero surgery for the treatment of spina bifida. Baby Charlotte's mother went into labor nearly 11 weeks after fetal closure was performed, and delivered on Saturday evening by cesarean section. Mother and baby are doing well. (Photo:...

2012-02-23 11:41:00

REDWOOD CITY, Calif., Feb. 23, 2012 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, announced today that it has commenced an action against Sequenom, Inc. and its wholly-owned subsidiary, Sequenom Center for Molecular Medicine, LLC ("Sequenom CMM"), in federal court. The action, filed in the Northern District of California, seeks a declaratory judgment that Verinata's cell-free DNA sequencing analysis techniques used in its...